Recurrent Chronic Subdural Hematoma Complicating HIV/HCV Cirrhosis: A “Repair Window” Therapeutic Hypothesis — Case Report

The brain is encased in a hard shell of bone, but it does not float freely inside. Between the brain and the skull lies a thin, delicate membrane that acts as a protective cushion. Sometimes, small blood vessels beneath this membrane can leak, slowly filling the space with blood. This condition, known as a chronic subdural hematoma, is like a slow leak in a tire; it builds up pressure over time, causing headaches, dizziness, and confusion. For most people, surgeons can drill a tiny hole to drain this fluid, and the body heals itself. However, the situation becomes far more dangerous when the patient's blood cannot clot properly. In people with severe liver disease or certain viral infections, the body may lack the platelets—the tiny cells responsible for stopping bleeding—needed to seal the leak. When the blood cannot clot, the hematoma often returns after surgery, creating a cycle of re-bleeding that is difficult to break.

In a case report published in October 2026, a team of doctors at Tongren People's Hospital in China described a patient caught in this exact cycle. The patient was a 43-year-old man living with a complex mix of health issues, including HIV and hepatitis C, which had damaged his liver and lowered his platelet count to a dangerously low level. He had already undergone two separate surgeries to drain a blood collection on the right side of his brain, only to see the problem return both times. When he was admitted a third time with a new, large collection of blood on the left side of his brain, the doctors faced a critical challenge. Standard surgery had failed twice, and the patient's body seemed unable to stop the bleeding on its own.

The medical team decided to try a new approach, not just by operating, but by timing a specific combination of treatments to a narrow window of time immediately after the surgery. They hypothesized that the first few days after draining the blood were a crucial "repair window," a brief period where the body was trying to stabilize the membrane and stop the leak. To support this repair, they introduced three therapies simultaneously. First, they gave the patient a medication called recombinant human thrombopoietin, which acts as a signal to the bone marrow to rapidly produce new platelets. Second, they continued a common cholesterol medication, atorvastatin, which has been shown in other studies to help stabilize the fragile membrane covering the brain. Third, they placed the patient in a hyperbaric oxygen chamber, where he breathed pure oxygen at high pressure to reduce swelling and improve healing in the brain tissue.

The results of this coordinated effort were striking. Before the treatment, the patient's platelet count was only 43, a level far too low to stop bleeding effectively. Within five days of starting the new regimen, his platelet count surged to 201, a level that allowed his blood to clot normally. The doctors monitored him closely, and by the time he was discharged forty days later, the blood collection had almost completely disappeared. Unlike his previous hospitalizations, where the bleeding returned quickly, this patient remained free of the condition for twelve months. He reported that his headaches, which had been a constant and distressing presence, finally faded away and stayed gone.

Despite this success, the authors of the report are careful not to claim they have found a guaranteed cure. They acknowledge that the patient had received other treatments in the past, such as blood transfusions and different medications, and that his own adherence to taking his medicines had been inconsistent. Because so many factors were at play, it is impossible to say with certainty that the new combination of therapies was the sole reason for his recovery. The doctors describe their work as a hypothesis-generating observation, meaning they have spotted a promising pattern that needs to be tested in larger, controlled studies before it can become a standard medical practice. They suggest that for patients with severe blood clotting problems, focusing on a specific "repair window" immediately after surgery might be the key to stopping the cycle of re-bleeding, but this idea remains a suggestion rather than a proven fact.

The case highlights a broader lesson in medical care: when a standard treatment fails, looking at the underlying causes of the patient's body can reveal new paths forward. In this instance, the doctors realized that simply draining the blood was not enough; they had to actively help the patient's body fix the clotting mechanism that was failing. While this single story does not solve the problem for everyone, it offers a clear direction for future research. It suggests that in the most difficult cases of brain bleeding, a proactive strategy that combines rapid platelet production, membrane stabilization, and oxygen therapy during the critical early days of recovery might offer a way out of a deadly loop. The medical community now has a specific, testable idea to explore, born from the experience of a patient who refused to give up and a team willing to try a new way of thinking.